Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient

a technology of astrocyte function and active ingredient, which is applied in the field of parkinson's disease treatment, can solve the problems of insufficient therapeutic benefit and decline of drug effect of antiparkinsonian drugs at presen

Inactive Publication Date: 2006-03-09
ONO PHARMA CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a new treatment for Parkinson's disease or Parkinson's syndrome. The treatment involves using an astrocyte function-improving agent as the active ingredient. The technical effect of this invention is to provide a more effective treatment for Parkinson's disease or Parkinson's syndrome.

Problems solved by technology

The technical problem addressed in this patent is the development of new treatments for Parkinson's disease and related nervous diseases that improve brain function and have beneficial effects on the symptoms of the disease. Current drugs used for treatment have limitations such as a decline in drug effect and side effects, and there is a need for more effective therapies.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient
  • Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient
  • Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient

Examples

Experimental program
Comparison scheme
Effect test

example 1

Improvement Effect of the Compound of the Present Invention in Experimental Model of Parkinson's Disease Induced by Administration of MPTP

[0067] Male C57BL / 6 mice (body weight: 20 to 28 g) were divided into groups each having 6 to 12 animals. Without anesthetizing, MPTP (10 mg / kg; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride) was intraperitoneally administered to the mice 4 times at intervals of 1 hour (Brain Res., 824: 224-231 (1999)). To the models thus prepared, Compound A of the present invention ((R)-2-propyloctanoic acid) was administered after 1, 6, 24 and 48 hours. Three days after the final administration, striata of the mice were collected. After weighing, the striata were immediately frozen and stored. Then, dopamine content and DOPAC (3,4-dihydroxypyenylacetate) content were measured by HPLC in a conventional manner and evaluated. Table 1 shows the results.

[0068] Dunnett's multiple comparison test (both sides) was performed on the basis of the data of the...

formulation example 1

Preparation of Capsules

[0072] (R)-2-propyloctanoic acid (1 g) was encapsulated into gelatin capsules to obtain 10 capsules each containing 100 mg of the active ingredient.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Contentaaaaaaaaaa
Stiffnessaaaaaaaaaa
Login to View More

Abstract

An agent for preventing and/or treating Parkinson's disease or Parkinson's syndrome, comprising, as an active ingredient, an astrocyte function-improving agent is disclosed. The astrocyte function-improving agent is preferably a compound represented by formula (I), a non-toxic salt thereof, or a hydrate thereof:
    • R5, R6, R11 and n are defined in the specification.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Owner ONO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com